Shots:
Amid rising R&D costs and tighter timelines, AI has evolved from a supporting tool to a central driver of biopharma deal-making, discovery strategies, and long-term value creation
AI-led licensing deals, platform partnerships, and new valuation models are reshaping biotech–pharma collaborations, with platforms and proprietary datasets increasingly rivaling or surpassing traditional pipelines in deal value…
